In conclusion, our study highlights that evaluation of Gli1 expression in advanced serous ovarian cancer may provide clinicians with important clues to prognosis, a finding needing confirmation in large-scale prospective clinical trials. The gene discussed is GLI1; the disease is ovarian serous adenocarcinoma.